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A 60-year-old man has been in your intensive care unit with
septic shock for 5 days and he has required a norepinephrine
infusion for the entire time. He had multisystem organ failure
but most of the organs have improved. He has good urine
output and does not have any evidence of heart failure. There
is no active bleeding and currently no signs of new or
ongoing infection. You wonder whether steroids might help
facilitate his recovery.
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Abstract
Decision-making in the intensive care unit is often very difficult. Although we are encouraged to make
evidence-based decisions, this may be difficult for a number of reasons. To begin with, evidence may
not exist to answer the clinical question. Second, when there is evidence it may not be applicable to
the patient in question or the clinician may be reluctant to apply it to the patient based on a number of
secondary issues such as costs, premorbid condition or possible complications. Finally, emotions are
often highly charged when caring for patients that have a significant chance of death, and care-givers
as well as families are frequently prepared to take chances on a therapy whose benefit is not entirely
clear. Steroid use in septic shock is an example of a therapy that makes some sense but has
conflicting support in the literature. In this issue of Critical Care Forum, the two sides of this often
heated debate are brought to the forefront in an interesting format.
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The scenario
Pro: steroids are useful in the management of septic shock
Frank V Ritacca, Carmine Simone and Randy Wax
Despite advances in providing care for patients with septic
shock, mortality rates remain unacceptably high.
Exogenous corticosteroids have potent anti-inflammatory
effects and their use for modulation of the host response in
septic shock has been debated for decades. Two meta-
analyses have suggested that high-dose steroids are not
beneficial in patients with septic shock [1,2]. These results
should not be generalized to treatment with low-dose
corticosteroids. We believe there are recent data showing
that low-dose corticosteroids hasten discontinuation of
vasopressors in refractory septic shock, and may improve
outcome.Critical Care    April 2002 Vol 6 No 2 Ritacca et al.
Demonstration of an intact hypothalamic–pituitary–adrenal
axis response has been associated with reduced mortality in
septic shock [3]. Corticosteroids can regulate the synthesis
and function of catecholamines and their receptors, which in
turn control vascular tone and organ perfusion [4].
Proinflammatory cytokines released in sepsis alter steroid
responsiveness, leading to the deleterious effects of
catecholamine dysfunction and refractory hypotension [5].
Downregulation of catecholamine receptors occurs with
prolonged use of exogenous catecholamines and this may be
reversed with administration of low-dose steroids [6].
Restoring endogenous regulation of vasomotor tone would
be desirable to preserve regional regulation of perfusion.
Three recent clinical trials have provided encouraging results
for the use of corticosteroids in septic shock (Table 1).
Patients were treated with corticosteroids at lower doses and
for a longer interval than in previous trials. Bollaert et al.
showed that patients receiving low-dose steroids had a
significantly higher rate of shock reversal (stable blood
pressure without fluid boluses or vasopressors) [7]. The
treatment effect was present irrespective of
hypothalamic–pituitary–adrenal axis function as measured by
an adrenocorticotrophic hormone (ACTH) stimulation test.
Briegel et al. similarly found that low-dose corticosteroids
could hasten independence from vasopressor support [8].
There were no trends suggesting treatment-related adverse
events in either trial. Although no mortality benefits were
found, increased rates of shock reversal may imply
decreased resource use (e.g. shorter length of stay in the
intensive care unit) and complications (e.g. catheter-related
infections).
Data published in abstract form from a multicenter trial testing
low-dose corticosteroid and mineralocorticoid support led to a
relative risk reduction of almost 30% in patients with septic
shock [9]. The survival benefit of combination therapy was
significant only in patients with blunted response to ACTH
stimulation. However, this may be due to a smaller number of
patients in the normal response group.
Finally, one retrospective study suggests that low-dose
corticosteroids may reduce post-traumatic stress disorder
and improve health-related quality of life in survivors of septic
shock [10].
Although exciting developments in targeted drug therapy for
sepsis have occurred recently, supportive care remains key
to maximizing survival in patients. We view appropriate
supplementation of corticosteroids as part of the regimen of
supportive care. Even if subsequent studies do not confirm a
mortality reduction, ‘fewer days of vasopressor dependence’
may itself be an important outcome. Given that the patient
described for this debate appears to have been adequately
treated for infection, repair of sepsis-induced dysregulation of
vasomotor tone using low-dose corticosteroids is reasonable
and appropriate.
Con: steroids are not useful in the management of septic shock
Katherine G Craig and Keith R Walley
The debate surrounding the use of corticosteroids in septic
patients has continued for over 30 years. Two meta-
analyses in the mid-1990s seemed to put an end to the
controversy. The conclusions drawn from these works were
that corticosteroids provided no benefit to patients with
septic shock [2] and that corticosteroids may actually
cause harm, as evidenced by a slight increase in overall
mortality [1].
Table 1
Summary of prospective studies suggesting benefit for use of corticosteroids in patients with septic shock
Study Design Therapy Outcome
Bollaert et al. [7] Prospective, randomized, double-blind,  100 mg hydrocortisone intravenously  Shock reversal at 7 days; treatment, 
placebo-controlled trial every 8 h for 5 days 68% (15/22); placebo, 21% (4/19). 
P = 0.007
Briegel et al. [8] Prospective, randomized, double-blind,  100 mg hydrocortisone intravenous  Median time to cessation of 
placebo-controlled trial loading dose plus infusion at  vasopressor support; treatment 
0.18 mg/kg/h until shock reversal,  (n = 20), 2 days versus placebo 
then wean infusion (n = 20), 7 days. P = 0.005
Annane [9] Prospective, randomized, double-blind,  50 mg hydrocortisone intravenously  28-day survival by Cox model, 28.8% 
placebo-controlled trial every 5 h + 50 µg fludrocortisone  relative risk reduction for treatment 
perorally once daily for 7 days (n = 150) versus placebo (n = 149). 
Relative risk, 0.712; 95% confidence 
interval, 0.525–0.965Available online http://ccforum.com/content/6/2/113
Pro’s response
Frank V Ritacca, Carmine Simone and Randy Wax
Applying data from trials using high-dose steroids is
inappropriate and leads to therapeutic nihilism. Life-saving
therapy, such as low-dose beta-blockers in severe
cardiomyopathy, met similar resistance because of poor
experiences with identical drugs given in higher doses
[18].
Levels of cortisol and responsiveness to ACTH stimulation in
patients with sepsis vary considerably [19–21]. A normal
corticotropin stimulation test result cannot exclude benefit of
low-dose corticosteroids [7,22]. Although this patient is not
‘most severely ill’, catecholamine receptor effects may be
more important than the immunomodulatory effects of this
therapy [22]. This patient remains a candidate for low-dose
corticosteroids.
Con’s response
Katherine G Craig and Keith R Walley
While the foundations of the pro/con debates are remarkably
similar, the resulting recommendations are not. Dr Ritacca
and colleagues suggest that “appropriate supplementation of
corticosteroids [be] part of the regimen of supportive care”.
There are several problems with this statement. First, with the
level of evidence currently available it must be recognized
that the use of steroids in sepsis, while promising, is still
experimental, and should not be given the same status as
routine measures of supportive care. Second, even if a
physician makes a conscious decision to try steroids, there
are again no data to suggest a dose or timing for ‘appropriate
supplementation’.
The debate has recently been re-opened by several small,
prospective, randomized, placebo-controlled trials. A study
by Bollaert et al., in which septic patients requiring
catecholamines were randomized to receive hydrocortisone
(100 mg intravenously three times a day for 5 days) or
placebo, found a significant reduction in the time it took to
reverse shock, and a trend towards improved survival [7].
While the results of this trial were impressive, care must be
taken not to overinterpret the results; it was a small clinical
trial with only about 20 patients in each arm, and there was a
relatively high mortality rate in the placebo arm (63%) for
patients with septic shock [11].
In a similar small trial by Briegel et al., septic shock patients
were randomized to receive either a placebo or hydrocortisone
(100 mg intravenous bolus), followed by continuous infusion
until septic shock resolved [8]. The length of time for which
vasopressor support was required was significantly reduced,
and measures such as mean arterial pressure and systemic
vascular resistance index were increased in patients treated
with steroids. In addition, there were trends toward earlier
reversal of organ dysfunction. There was not, however, a
mortality difference between the two groups [8].
It may be germane to recognize that all benefit of
immunomodulatory therapy in adequately powered,
randomized, controlled trials is confined to the most severely
ill [12–15]. This does not fit with the patient described in the
aforementioned scenario.
Clinical case
In view of conflicting older, yet strong, evidence (that high-
dose steroids are not beneficial) and newer, yet preliminary,
studies (that suggest low-dose steroids are beneficial), the
question becomes one of whether steroid-induced reversal of
vasopressor support confers any outcome benefits.
Unfortunately, no definitive work has been published.
The patient described in the present scenario is improving in
all aspects of organ failure, but remains catecholamine
dependent. A thorough examination and review of his
management needs to be conducted to ensure no reversible
cause of hypotension can be determined. A corticotropin
stimulation test should be performed and absolute adrenal
insufficiency should be treated.
There is ongoing debate in the literature as to the
usefulness of this corticotropin stimulation test in so-called
‘relative adrenal insufficient’ patients, although it may be of
prognostic significance [16]. A recent study by Schroeder
et al. found low basal plasma cortisol levels and diminished
responses to corticotropin-releasing hormone in patients
that died of septic shock as compared with those who
survived [17]. Annane et al., however, found an elevated
basal cortisol level (≥34 µg/dl) and a poor response to
corticotropin (e.g. ≤9 µg/dl elevation at 30 or 60 min) to
be a predictor of the poorest survival in patients with
sepsis [3].
At this point in time there is not sufficient evidence to guide
clinical practice. We therefore do not advocate use of
steroids in this clinically improving patient without another
indication. We must be cautious in our enthusiasm to try new
therapies as history provides many examples of promising
small clinical trials that have not held up to the test of time
and larger, multicentered trials.Critical Care    April 2002 Vol 6 No 2 Ritacca et al.
Much work remains to be carried out in this field. We urge
restraint and recognition of the potential adverse side effects
of, and lack of clear evidence for, steroid therapy in sepsis.
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